FGF21 and LEPR polymorphisms predict valproate treatment outcome in patients with bipolar II disorder
碩士 === 國立成功大學 === 臨床藥學與藥物科技研究所 === 105 === Background: Valproate (VPA) is a mood stabilizer for treating patients with bipolar disorder (BD), and it is known to be one of risk factors associated with metabolic disturbances in BD patients. Recent studies had pointed out the metabolic regulation and m...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | en_US |
| Published: |
2018
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/ub5vpx |